Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >= 1.6 log(10) copies/ml at all twice daily doses >= 100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.